Don’t miss the latest developments in business and finance.

Orchid Pharma receives EIR report on closure of PADE inspection

Image
Capital Market
Last Updated : Jan 08 2018 | 8:16 PM IST

By USFDA

Orchid Pharma has received the Establishment Inspection Report from USFDA based on the successful inspection closure for the Post-marketing Adverse Drug Experience reporting Inspection (PADE) conducted at Orchid Tower 313, Valluvar Kottam High Road, Nungambakkam, Chennai. The facility was inspected by USFDA in the month of June 2017.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

More From This Section

First Published: Jan 08 2018 | 7:58 PM IST

Next Story